csb-001
Recombinant proteinexperimental
Clinical trial activity
3 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Aug 24, 2021 (NCT04909450)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
HGFAC agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06452316 | Phase 1 | May 15, 2024 | Clarus Therapeutics, Inc. |
| NCT06257355 | Phase 1 | Feb 5, 2024 | Clarus Therapeutics, Inc. |
| NCT04909450 | Phase 1/Phase 2 (Phase 2) | Aug 24, 2021 | Clarus Therapeutics, Inc. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Clarus Therapeutics, Inc. | For profit | 3 | 3 | 2 | 2021 |
1 organizations
Page 1 / 1